Answers are grounded in this paper and cite their sources.
Long-term outcomes after perioperative immunochemotherapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma remain incompletely characterised. In this single-arm phase II trial (NCT04354662), 51 patients with locally advanced G/GEJ received toripalimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel before surgery with postoperative treatment were enrolled. The reported co-primary endpoints were primary-tumour pathological complete response and 3-year DFS. With median follow-up of 63.1 months, primary-tumour complete response was 19.6% (10/51), whereas nodal-inclusive ypT0N0 response was 13.7% (7/51). Three-year DFS was 52.9% (95% CI, 38.5%-65.5%), 5-year OS was 59.0% (42.9%-71.9%). Grade ≥3 reported treatment-related adverse events occurred in 72.5% of patients. Pretreatment biopsies from 24 patients underwent multiplex immunofluorescence. Higher stromal CD3 positivity was nominally associated with longer survival after median dichotomization, but continuous-variable associations were nonsignificant and no feature survived false-discovery-rate correction. Findings support independent investigation of stromal CD3 positivity but establish neither comparative benefit nor biomarker validity.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: